We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

Two Drugs Slash Risk of Stroke Recurrence

By HospiMedica staff writers
Posted on 12 Jul 2001
A landmark six-year study has discovered that two drugs for lowering blood pressure, even when administered to stroke patients who did not have high blood pressure, reduced the risk of further strokes and heart attacks by 25-50%. More...
The results of the study, conducted by an independent group of medical researchers, were presented at the European Society of Hypertension (ESH) in Milan (Italy).

The study involved 6,000 high-risk stroke sufferers in 172 hospitals, who were treated with two blood-pressure drugs (perindopril and indapamide) over a period of five years. One in every ten (10%) avoided either death, heart attack, or further during that period. The drugs also reduced the risk of serious complications of stroke such as disability and dementia. According to world health statistics, about 20% of high-risk stroke patients suffer another stroke or heart attack within five years. More than two-thirds of all strokes occur in people who do not have high blood pressure as defined by the World Health Organization (WHO).

Currently, blood pressure drugs are given mainly to a minority of people who suffer a stroke or transient ischemic attack. Aspirin is the only treatment given widely to patients after stroke, but it is not suitable for people who have suffered some particularly dangerous types of stroke, such as cerebral hemorrhage. In the study, perindopril, an ACE (angiotensin-converting enzyme) inhibitor, and indapamide together reduced the risk of stroke by 75% among patients who had previously suffered a cerebral hemorrhage.

"There is a strong case for making these drugs available to most stroke patients, irrespective of their age and blood pressure and irrespective of the other treatments they may be receiving,” said Professor Stephen MacMahon, of the University of Sydney (Australia), one of the study's organizers. "The benefits are unusually large and occur in a wide range of patients. There were very few side effects.”




Related Links:
Univ. of Sydney

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Hybrid Arch Device
Neo EDE
New
Radiofrequency Generator
GX1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.